Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

UC Regents

Neither a doctor nor a teaching hospital

Research payments

$2,592,651

93 payments

Through program year 2025, UC Regents is reported as receiving $2,592,651 in research payments, across 93 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $106,818 3
2024 Research $164,644 5
2023 Research $681,408 16
2022 Research $1,282,255 40
2021 Research $147,420 11
2020 Research $52,723 5
2019 Research $157,383 13

Breakdown

Who paid Research payments · program years 2019–2025
  1. Ge Healthcare $862,509 15 payments
  2. AstraZeneca UK Limited $790,527 13 payments
  3. Tandem Diabetes Care, Inc. $262,439 25 payments
  4. AstraZeneca Pharmaceuticals LP $138,915 7 payments
  5. Actelion Pharmaceuticals US, Inc. $138,228 3 payments
  6. Acerta Pharma LLC $129,185 2 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $121,355 9 payments
  8. Genzyme Corporation $50,000 1 payment
  9. Ucb SA $33,588 1 payment
  10. Sanofi US Services Inc. $31,795 8 payments
Studies the money was for Research payments · program years 2019–2025
  1. AZD2693, Cardiovascular, Renal and Metabolism $404,976 3 payments
  2. Multiorgan Localization Autopilot $273,284 3 payments
  3. MRI technology development/evaluation $169,744 3 payments
  4. Quantitative CBF and Blood Brain Barrier Permeability Imaging $158,214 3 payments
  5. Slp-C-23-USA-008-V01 $149,476 4 payments
  6. t:slim X2 insulin pump with Control-IQ technology US Post-Approval Study $138,829 22 payments
  7. A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia $129,185 2 payments
  8. Control-IQ 1.5 Post Approval Study (CLIO Mini) $117,417 2 payments
  9. MAJIC A Phase III Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib plus Venetoclax versus Venetoclax plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma $103,167 1 payment
  10. A Modular Phase I/II, Open-label, Multicentre Study to Assess AZD4573 in Novel Combinations with Anti-cancer Agents in Patients with Advanced Haematological Malignancies $102,487 1 payment
What the money was spent on Research payments · program years 2019–2025
  1. Other $121,985 10 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record